The Global Market for Peripheral Arterial Disease (PAD) Therapeutics is Projected to Reach US$957.3 Million by 2022

Rising Prevalence of Hypertension & its Comorbid Risk of Atherosclerosis to Benefit the Market for Peripheral Arterial Disease Therapeutics, According to a New Report by Global Industry Analysts, Inc.

GIA launches comprehensive analysis of industry segments, trends, growth drivers, market share, size and demand forecasts on the global Peripheral Arterial Disease (PAD) Therapeutics market. The global market for Peripheral Arterial Disease (PAD) Therapeutics is projected to reach US$957.3 million by 2022, driven by the rise in numerous risk factors that trigger fatty deposits in arteries, especially high prevalence of hypertension which considerably raises the risk of developing atherosclerosis.

Peripheral arterial disease (PAD) refers to a condition characterized by narrowing of the peripheral arteries of the body, which comprise arteries of the extremities, especially those of the legs. PAD occurs as a result of plaque build-up inside the arteries that carry blood to the head, limbs and organs. While the high prevalence of global Peripheral Artery Disease places significant burden on the health and economic systems, low awareness levels and sub-optimal care remains a major issue. Besides ageing, PAD is linked to the risk of cardiovascular disease aortic aneurysms, hypertension and diabetes as well. Given the high incidence of PAD as a result of advancing age and other risk factors, there is high focus on drugs or devices to treat and manage the condition. The market is also expected to benefit from new PAD drugs in the pipeline.

Despite initial interventions to free blocked leg arteries, recurrence is a common characteristic of PAD. The PAD therapeutics market therefore offers significant potential for new drug therapies as there is a high unmet need. Treatment of critical limb ischemia, the most advanced stage of Peripheral Arterial Disease also presents considerable potential for the development of new therapies and procedures. Antiplatelets constitute the major treatment for PAD. Following the loss of market exclusivity of Plavix (clopidogrel), the leading first-generation drug used in the treatment of PAD, in 2012, there has been growing competition from less expensive generics and increasing industry focus on the development of novel drug therapies. While Astra Zeneca’s Brilinta/Brilique (ticagrelor) was forecast to be a strong successor to Plavix, the drug failed to demonstrate benefit over clopidogrel. Among other drugs in pipeline is Bayer’s anticoagulant Xarelto® (rivaroxaban), which is undergoing clinical trials for the treatment of peripheral arterial disease.

As stated by the new market research report on Peripheral Arterial Disease (PAD) Therapeutics, the United States and Europe represent the largest markets worldwide. Asia-Pacific ranks as the fastest growing market with a CAGR of 8.5% over the analysis period, led by factors such as growing population and a parallel increase in healthcare burden, improving diagnosis rate and awareness about available treatment options, developing healthcare infrastructure and improved access to quality healthcare, rising healthcare spending among the emerging base of affluent middle class population, and changing patterns of health as a result of social change and globalization of unhealthy lifestyle practices.   

Major players covered in the report include AstraZeneca Plc., Bayer HealthCare Pharmaceuticals, Bristol-Myers Squibb Company, Merck & Co., Inc., Proteon Therapeutics, Inc., Sanofi S.A., Symic Bio, Inc., and TheraVasc, Inc., among others.

The research report titled "Peripheral Arterial Disease (PAD) Therapeutics: A Global Strategic Business Report" announced by Global Industry Analysts Inc., provides a comprehensive review of market trends, growth drivers, mergers and acquisitions, and other strategic industry activities of major companies worldwide. The report provides market estimates and projections for geographic markets, such as the US, Canada, Japan, Europe (France, Germany, Italy, UK, Spain, and Rest of Europe), Asia-Pacific (China, and Rest of Asia-Pacific), Latin America, and Rest of World.  

Global Industry Analysts, Inc. 6150 Hellyer Ave., San Jose CA 95138, USA, All Rights Reserved.